A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats

Neurogastroenterology and Motility

Volumn 24, Issue 4, 2012, Pages

  Agostini, S ^a   Goubern, M ^b   Tondereau, V ^a   Salvador Cartier, C ^a   Bezirard, V ^a   Leveque M ^a   Keranen H ^a,c   Theodorou, V ^a   Bourdu Naturel, S ^b   Goupil Feuillerat, N ^b   Legrain Raspaud, S ^b   Eutamene, H ^a  

^a TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

^b Danone Research Centre Carasso   (France)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Fermented milk; Gut barrier; Irritable bowel syndrome; Pain; Probiotics

Indexed keywords

ENDOTOXIN; JUNCTIONAL ADHESION MOLECULE A; OCCLUDIN; PROBIOTIC AGENT;

ACUTE STRESS; ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; COLONY FORMING UNIT; CONTROLLED STUDY; DAIRY PRODUCT; DOSE RESPONSE; FEMALE; FERMENTED PRODUCT; HYPERALGESIA; IMMOBILIZATION STRESS; INTESTINAL DYSMOTILITY; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BIFIDOBACTERIUM; COLON; CULTURED MILK PRODUCTS; DISEASE MODELS, ANIMAL; FEMALE; HYPERESTHESIA; IMMOBILIZATION; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; PAIN THRESHOLD; PROBIOTICS; RATS; RATS, WISTAR; STRESS, PSYCHOLOGICAL;

EID: 84858290900     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2011.01865.x     Document Type: Article

References (43)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
2. Whitehead WE. Psychosocial aspects of functional gastrointestinal disorders. Gastroenterol Clin North Am 1996; 25: 21-34.
3. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58: 196-201.
4. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41-6.
5. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-94.
6. Ait-Belgnaoui A, Bradesi S, Fioramonti J, Theodorou V, Bueno L. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005; 113: 141-7.
7. Tsukita S, Furuse M, Itoh M. Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol 1999; 11: 628-33.
8. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 2000; 279: G851-7.
9. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003; 124: 1662-71.
10. Shanahan F. Irritable bowel syndrome: shifting the focus toward the gut microbiota. Gastroenterology 2007; 133: 340-2.
11. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306-14.
12. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33.
13. Spiller RC. Potential biomarkers. Gastroenterol Clin North Am 2011; 40: 121-39.
14. Fuller R. Probiotics in human medicine. Gut 1991; 32: 439-42.
15. Mack DR, Lebel S. Role of probiotics in the modulation of intestinal infections and inflammation. Curr Opin Gastroenterol 2004; 20: 22-6.
16. Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-9.
17. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-14.
18. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007; 19: 166-72.
19. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008; 103: 1557-67.
20. Eutamene H, Lamine F, Chabo C, et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 2007; 137: 1901-7.
21. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
22. Whorwell PJ, Altringer L, Morel J et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-90.
23. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009; 29: 104-14.
24. Marteau P, Cuillerier E, Meance S et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther 2002; 16: 587-93.
25. Guyonnet D, Chassany O, Ducrotte P et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-86.
26. Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 2009; 102: 1654-62.
27. Williams CL, Peterson JM, Villar RG, Burks TF. Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol 1987; 253: G582-6.
28. Morteau O, Hachet T, Caussette M, Bueno L. Experimental colitis alters visceromotor response to colorectal distension in awake rats. Dig Dis Sci 1994; 39: 1239-48.
29. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108: 1566-81.
30. Agrawal A, Houghton LA, Reilly B, Morris J, Whorwell PJ. Bloating and distension in irritable bowel syndrome: the role of gastrointestinal transit. Am J Gastroenterol 2009; 104: 1998-2004.
31. Houghton LA, Whorwell PJ. Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. Neurogastroenterol Motil 2005; 17: 500-11.
32. Verdu EF, Bercik P, Bergonzelli GE et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127: 826-37.
33. Kamiya T, Wang L, Forsythe P et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55: 191-6.
34. Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM, Schiffrin EJ. Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. J Dairy Sci 1999; 82: 863-9.
35. Sharp MD, McMahon DJ, Broadbent JR. Comparative evaluation of yogurt and low-fat cheddar cheese as delivery media for probiotic Lactobacillus casei. J Food Sci 2008; 73: M375-7.
36. Saxelin M, Lassig A, Karjalainen H et al. Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese. Int J Food Microbiol 2010; 144: 293-300.
37. Pochart P, Marteau P, Bouhnik Y, Goderel I, Bourlioux P, Rambaud JC. Survival of bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992; 55: 78-80.
38. Rochet V, Rigottier-Gois L, Ledaire A et al. Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product - a randomised study in healthy adults. J Mol Microbiol Biotechnol 2008; 14: 128-36.
39. Berrada N, Lemeland JF, Laroche G, Thouvenot P, Piaia M. Bifidobacterium from fermented milks: survival during gastric transit. J Dairy Sci 1991; 74: 409-13.
40. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52: 988-97.
41. Ferrier L, Mazelin L, Cenac N et al. Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. Gastroenterology 2003; 125: 795-804.
42. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
43. Barreau F, Ferrier L, Fioramonti J, Bueno L. Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats. Gut 2004; 53: 501-6.